WilliamBruceDonnellanMD

PubMed

• A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia.
  Sudhir Manda, Bertrand M Anz 3rd, Christopher Benton, E Randolph Broun, Habte A Yimer, John S Renshaw, George Geils Jr, Jesus Berdeja, Jose Cruz, Jason M Melear, Suzan...> ;Hematological Oncology. 2024 May 1
• First-in-human study of JNJ-67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome.
  Rupa Narayan, Ana Alfonso Piérola, William B Donnellan, Antonieta Molero Yordi, Maher Abdul-Hay, Uwe Platzbecker, Marion Subklewe, Tapan Mahendra Kadia, Juan Manuel Al...> ;Clinical and Translational Science. 2024 Mar 1
• Post-remission cytopenia management in patients with AML treated with venetoclax in combination with hypomethylating agents: Pre- versus post-VIALE-A real-world experi...
  Pankit Vachhani, Esprit Ma, Tao Xu, Melissa Montez, Sarah Worth, Archibong Yellow-Duke, Wei-Han Cheng, Michael E Werner, Jonathan Abbas, William Donnellan> ;Cancer Medicine. 2023 Sep 1
• 1 citations
  Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic Malignancies.
  Manish R Patel, William Donnellan, Michael Byrne, Adam S Asch, Amer M Zeidan, Maria R Baer, Amir T Fathi, Andrew T Kuykendall, Fred Zheng, Chris Walker, Lulu Cheng, Ci...> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Sep 1
• 1 citations
  Lenalidomide and Eltrombopag for Treatment of Low- or Intermediate-Risk Myelodysplastic Syndrome: Result of a Phase II Clinical Trial.
  Gonzalez-Lugo, J., Kambhampati, S., Yacoub, A., Donnellan, W., Berdeja, J., Bhagat, P., Fehn, K., Remy, C., Jasra, S., Kazemi, M., Pradhan, K., Kim, M., Mantzaris, I.,...> ;Clinical Cancer Research. 2023 Jan 4
• 10 citations
  First-in-human study of JNJ-63709178, a CD123/CD3 targeting antibody, in relapsed/refractory acute myeloid leukemia.
  Michael Boyiadzis, Pinkal Desai, Nikki Daskalakis, William Donnellan, Lucille Ferrante, Jenna D Goldberg, Michael R Grunwald, Christina Guttke, Xiang Li, Jose Antonio ...> ;Clinical and Translational Science. 2023 Mar 1
• 37 citations
  Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.
  Justin M Watts, Maria R Baer, Jay Yang, Thomas Prebet, Sangmin Lee, Gary J Schiller, Shira N Dinner, Arnaud Pigneux, Pau Montesinos, Eunice S Wang, Karen P Seiter, And...> ;The Lancet. Haematology. 2023 Jan 1
• 13 citations
  Venetoclax and Hypomethylating Agents as First-line Treatment in Newly Diagnosed Patients with AML in a Predominately Community Setting in the US.
  Pankit Vachhani, Evelyn M Flahavan, Tao Xu, Esprit Ma, Melissa Montez, Anda Gershon, Maika Onishi, Huan Jin, Grace Ku, Brannon Flores, Cat N Bui, Jonathan A Abbas, Wil...> ;The Oncologist. 2022 Nov 3
• 12 citations
  Atezolizumab alone or in combination did not demonstrate a favorable risk-benefit profile in myelodysplastic syndrome.
  Aaron T Gerds, Bart L Scott, Peter Greenberg, Tara L Lin, Daniel A Pollyea, Amit Verma, Monique Dail, Yuning Feng, Cherie Green, Connie Ma, Bruno C Medeiros, Mark Yan,...> ;Blood Advances. 2022 Feb 22
• The impact of early versus late tocilizumab administration in patients with cytokine release syndrome secondary to immune effector cell therapy
  Rachel Peaytt, Laura Beth Parsons, Darby Siler, Rachel Matthews, Belinda K. Li, David Bell, Carlos Bachier, Jeremy Pantin, Jesus G. Berdeja, Ian W. Flinn, William B. D...> ;Journal of Oncology Pharmacy Practice. 2021 Nov 24
• 7 citations
  A 2:1 randomized, open-label, phase II study of selinexor vs. physician's choice in older patients with relapsed or refractory acute myeloid leukemia.
  Kendra Sweet, Bhavana Bhatnagar, Hartmut Döhner, Will Donnellan, Olga Frankfurt, Michael Heuser, Vamsi Kota, Hongtao Liu, Emmanuel Raffoux, Gail J. Roboz, Christoph Rö...> ;Leukemia & Lymphoma. 2021 Jul 29
• 84 citations
  KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results.
  Bijal D. Shah, Michael R. Bishop, Olalekan O. Oluwole, Aaron C Logan, Maria R. Baer, William B. Donnellan, Kristen M. O'Dwyer, Houston Holmes, Martha Arellano, Armin G...> ;Blood. 2021 Jul 8
• 230 citations
  Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia
  Gail J. Roboz, Courtney D. DiNardo, Eytan M. Stein, Stéphane de Botton, Alice S. Mims, Gabrielle T. Prince, Jessica K. Altman, Martha Arellano, Will Donnellan, Harry P...> ;Blood. 2020 Feb 13
• 21 citations
  A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis.
  Stephen Couban, Giulia Benevolo, William B. Donnellan, Jennifer Cultrera, Steffen Koschmieder, Srdan Verstovsek, Gregory Hooper, Christian Hertig, Maneesh Tandon, Nata...> ;Journal of Hematology & Oncology. 2018 Sep 24
• 884 citations
  Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
  Courtney D. DiNardo, Eytan M. Stein, S. de Botton, Gail J. Roboz, Jessica K. Altman, Alice S. Mims, Ronan T. Swords, Robert H. Collins, Gabriel N. Mannis, Daniel A. Po...> ;The New England Journal of Medicine. 2018 Jun 2
• 1 citations
  A Phase II Trial Evaluating the Safety of Rapid Infusion of Ofatumumab in Patients with Previously Treated Chronic Lymphocytic Leukemia
  William B. Donnellan, Jesus G. Berdeja, Diana Shipley, Edward Arrowsmith, David Wright, Scott D. Lunin, Richard H. Brown, James Essell, Ian W. Flinn> ;The Oncologist. 2017 Oct 1
• 4 citations
  Phase II study of bendamustine, bortezomib and dexamethasone (BBD) in the first-line treatment of patients with multiple myeloma who are not candidates for high dose c...
  Jesus G. Berdeja, Todd M. Bauer, Edward Arrowsmith, James Essell, Patrick Murphy, James A. Reeves, Ralph V. Boccia, William B. Donnellan, Ian W. Flinn> ;British Journal of Haematology. 2017 Apr 1
• 47 citations
  Examining racial differences in diffuse large B-cell lymphoma presentation and survival
  Christopher R. Flowers, Pareen J. Shenoy, Uma Borate, Kevin Bumpers, Tanyanika Douglas-Holland, Nassoma King, Otis W. Brawley, Joseph Lipscomb, Mary Jo Lechowicz, Rajn...> ;Leukemia & Lymphoma. 2013 Feb 1
• Join now to see all